Practical implication
Regulatory intelligence teams should review ongoing studies and compliance with postmarketing requirements for the drugs listed, specifically focusing on their deadlines for completion and the nature of the studies required.
The FDA has ongoing accelerated approvals for several drugs targeting infectious diseases. These approvals come with postmarketing requirements (PMRs) to verify clinical benefits through further studies. Notably, Hepcludex for chronic hepatitis delta virus infection has an accelerated approval date of May 22, 2026, and a PMR completion date set for June 30, 2034. Benznidazole for Chagas disease has a PMR completion date of May 31, 2026, while Arikayce for MAC lung disease has a PMR deadline of June 30, 2024.
What changed: The FDA has updated its list of ongoing accelerated approvals for infectious disease treatments, now detailing specific requirements for clinical studies to verify the clinical benefits of these drugs.
Why it matters: Monitoring postmarketing commitments is crucial to ensure that drugs maintain their safety and efficacy profiles, especially for products approved under expedited processes without fully established clinical benefits.
Practical implication: Regulatory intelligence teams should review ongoing studies and compliance with postmarketing requirements for the drugs listed, specifically focusing on their deadlines for completion and the nature of the studies required.
View original source
- Source: FDA - What's New Drugs RSS
- Published at source: 2026-08-25T00:00:00.000Z
- Discovered by monitor: 2026-08-25T19:36:40.013Z
Published from the regulator source ingestion pipeline after PV impact triage.
